Want to see INMD full AI Analyst Report?
Earnings Data
Report Date
Jul 23, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.33Last Year’s EPS
0.47Same Quarter Last Year
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call contained a mix of modest top-line progress and strategic positives (5% revenue growth, strong cash balance, product launches, sales reorganization and share repurchases) offset by notable margin compression, rising operating expenses and declines in EPS. Management provided steady full-year guidance and described early signs of stabilization in the U.S., but profitability pressures and macroeconomic headwinds temper the outlook. International and product development initiatives offer upside, while near-term margin and demand uncertainty are the primary negatives.Company Guidance
Revenue Growth
Total revenue of $82.0M in Q1 2026, up 5% from $77.9M in Q1 2025, driven primarily by stronger U.S. performance.
Solid International Mix and Growth
International sales of $38.7M represented 48% of total sales and increased ~2.65% year-over-year; company operates in 100+ countries with Europe performing strongly.
Strong Balance Sheet and Cash Generation
Cash, cash equivalents, marketable securities and deposits totaled $537.2M as of 3/31/2026; generated $15.4M from operating activities in Q1.
Product Momentum — Laser Platforms Contributing
Newer platforms (Pico and CO2) made meaningful contributions to Q1 revenue and expand the company’s procedure offering; Erbium laser development targeting FDA clearance by year-end to further broaden portfolio.
Sales Organization Changes and Early Stabilization
North America reorganized to a unified model (new leadership installed end of Q3 2025) and Envision ophthalmology/optometry sales force now operates independently (30 reps); management reports early signs of stabilization, especially in the U.S., with particularly strong progress in March.
Capital Return and Optionality
Significant share repurchases: $127.4M repurchased in 2025 and $52.7M year-to-date under the 2026 program (~3.86M shares YTD); management states all capital allocation options (buybacks, M&A, dividends) remain on the table.
Clear 2026 Guidance Provided
Reiterated full-year 2026 guidance: revenue $365M–$375M; non-GAAP gross margin 74%–76%; non-GAAP income from operations $73M–$78M; non-GAAP diluted EPS $1.33–$1.38.
INMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $14.40 | $13.59 | -5.63% |
Feb 10, 2026 | $15.12 | $14.62 | -3.31% |
Nov 05, 2025 | $14.63 | $14.53 | -0.68% |
Jul 30, 2025 | $14.31 | $13.90 | -2.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Inmode (INMD) report earnings?
Inmode (INMD) is schdueled to report earning on Jul 23, 2026, After Close (Confirmed).
What is Inmode (INMD) earnings time?
Inmode (INMD) earnings time is at Jul 23, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INMD EPS forecast?
INMD EPS forecast for the fiscal quarter 2026 (Q2) is 0.33.
